Frontlight ResearchEarly access
CompletedNo phase
A Pre-market, Two-stages Interventional Clinical Investigation to Evaluate the Safety and the Performance of Fibroin Syrup in Reducing the Gastroesophageal Reflux Disease (GERD) Symptomatology in Nonerosive Reflux Disease (NERD) Patients
Key facts
- Who runs it
- Rose Pharma SA
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 47 people enrolled
- Started
- 24 Jul 2024
- Ended
- 8 Aug 2025
- Type of study
- Interventional
- Treatments tested
- Syrup made by hyaluronic acid
- Record updated
- 4 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Patient who signed Informed consent form
- Male or Female over 18 years old at the time of the signature of the Informed consent form
- Symptomatic non-erosive reflux disease (heartburn and/or regurgitation) for at least 8 weeks
- RDQ (Reflux Disease Questionnaire) score ≥ 12 at baseline (questionnaire specific for reporting the frequency and severity of upper gastrointestinal symptoms)
- Willingness to follow all study procedures, including attending all site visits, tests and examinations
Who cannot take part
- Use of proton pump inhibitors or H2 receptor antagonists in the previous 4 weeks
- Simultaneous participation in an interventional study or participation in an interventional study in the last 1 month before study inclusion
- Known drug and/or alcohol abuse
- Diagnosis of Helicobacter pylori infection
- Uncontrolled cardiac, renal, liver or pulmonary disease
- Diabetes
- Active malignant neoplasia
- Known allergy to device components
- Esophagitis according to the Los Angeles classification (grade A to D)
- Pregnancy or breast-feeding
- Mental incapacity that precludes adequate understanding or cooperation
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study involves a medical device in the form of syrup, not yet on the market and tested for the first time in humans, named "FIBROIN SYRUP". The intended use is to reduce the GastroEsophageal Reflux Disease (GERD) symptoms such as heartburn, epigastric pain, irritative and nocturnal cough, dysphagia and dysphonia, which may occur especially after meals or during the night due to lying position. "FIBROIN SYRUP" has never been tested on humans and this study aims to evaluate the safety, tolerability and efficacy of the medical device when taken after the main meals (breakfast, lunch, and dinner; total: 3 sticks/day) for 6 weeks.
The group in the trial
- Adult patients suffering from gastroesophageal reflux diseaseTreatment being tested
Treatment: Syrup made by hyaluronic acid
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 4 May 2026